This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing Coherus' POLARIS-02 and JUPITER-02 studies and the potential of LOQTORZI (toripalimab-tpzi) in nasopharyngeal carcinoma
Ticker(s): CHRSWho's the expert?
Institution: University of Michigan
- Clinical professor medicine, practicing oncology at the Rogel Cancer Center, Oncology Research Professor of Thyroid Cancer, & Co-chair of the Head and Neck and Endocrine Cancers Clinical Research Team.
- Specializes in the treatment of head and neck and thyroid malignancies and treats 4 patients a year with nasopharyngeal carcinoma (NPC).
- Contributed to the publications of landmark clinical trials that have ultimately led to the FDA approval of two small molecule inhibitors to treat metastatic iodine-refractory and medullary thyroid cancers.
Interview GoalThis conversation will focus on the standard of care and the potential of LOQTORZI (toripalimab-tpzi), a next-generation anti-PD-1 monoclonal antibody as treatment for Nasopharyngeal Carcinoma.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
